Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Invested Capital (2021 - 2026)

bioAffinity Technologies has reported Invested Capital over the past 6 years, most recently at $4.3 million for Q1 2026.

  • Quarterly Invested Capital rose 95.35% to $4.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Mar 2026, up 95.35% year-over-year, with the annual reading at $7.9 million for FY2025, 130.98% up from the prior year.
  • Invested Capital was $4.3 million for Q1 2026 at bioAffinity Technologies, down from $7.9 million in the prior quarter.
  • Over five years, Invested Capital peaked at $22.0 million in Q3 2022 and troughed at -$16.8 million in Q2 2022.
  • The 5-year median for Invested Capital is $6.1 million (2023), against an average of $4.2 million.
  • Year-over-year, Invested Capital surged 261.16% in 2022 and then crashed 143.82% in 2025.
  • A 5-year view of Invested Capital shows it stood at $11.3 million in 2022, then tumbled by 46.38% to $6.1 million in 2023, then crashed by 43.17% to $3.4 million in 2024, then skyrocketed by 130.98% to $7.9 million in 2025, then plummeted by 46.46% to $4.3 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Invested Capital are $4.3 million (Q1 2026), $7.9 million (Q4 2025), and $9.0 million (Q3 2025).